- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 1,321
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Dan Zandberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Epoetin Alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 89
- States / cities
- Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
- Conditions
- Chronic Lymphocytic Leukemia, Richter Syndrome
- Interventions
- Umbralisib, ublituximab, TG-1501
- Drug · Biological
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 4
- States / cities
- New York, New York • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
- Conditions
- Pemphigus
- Interventions
- Sirolimus (formerly known as Rapamycin)
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Coronary Heart Disease, Myocardial Infarction
- Interventions
- Titration of medications, Lifestyle Counseling, Medication Counseling, Usual Care with Medication Reconciliation
- Other · Behavioral
- Lead sponsor
- Middle Tennessee Research Institute
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension
- Interventions
- Nicotine Replacement Therapy, Diet
- Drug · Behavioral
- Lead sponsor
- Mark Vander Weg
- Other
- Eligibility
- Not listed
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Rochester, Minnesota
- Conditions
- Cancer Pain, Chronic Pain, Cancer Associated Pain, Neuropathic Pain
- Interventions
- Intrathecal Targeted Drug Delivery, Conservative medical management
- Device · Combination Product
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Oshkosh, Wisconsin
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- FG-3246
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 23
- States / cities
- Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 18 more
- Conditions
- Covid19
- Interventions
- C144-LS and C-135-LS
- Biological
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ewing Sarcoma, Colorectal Adenocarcinoma
- Interventions
- INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
- Conditions
- Multiple Myeloma
- Interventions
- Bendamustine, Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Suzanne Lentzsch, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent, Non-squamous EGFR Wt NSCLC, Platinum Resistant Ovarian Cancer, PROC
- Interventions
- HWK-007
- Drug
- Lead sponsor
- Whitehawk Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 9 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, 11C-YJH08, Optional Tumor Biopsy
- Procedure · Drug
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2033
- U.S. locations
- 59
- States / cities
- Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
- Conditions
- Prostatic Neoplasm
- Interventions
- Perflutren Lipid Microsphere Intravenous Suspension
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertension
- Interventions
- Standard Care, Intensive Treatment
- Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 55 Years to 79 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- SLC6A1
- Interventions
- Glycerol Phenylbutyrate
- Drug
- Lead sponsor
- Scripps Translational Science Institute
- Other
- Eligibility
- 2 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Smoking Cessation
- Interventions
- Varenicline, Bupropion, Placebo, Counseling/Phone Calls
- Drug · Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 641 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
- Interventions
- TS-104
- Drug
- Lead sponsor
- TwoStep Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Maumee, Ohio • Portland, Oregon • Fairfax, Virginia
- Conditions
- Hematologic Malignancies
- Interventions
- Stem Cell Transplant, G-CSF, Fludarabine, cyclophosphamide, Cyclosporine, Methotrexate
- Procedure · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2020
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Congenital Heart Disease, SRV Dependent
- Interventions
- Autologous mononuclear cells
- Biological
- Lead sponsor
- Timothy J Nelson, MD, PhD
- Other
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more
- Conditions
- Opioid-use Disorder, Substance Use Disorders, Parenting
- Interventions
- pCARE, Standard Early Intervention services
- Behavioral · Other
- Lead sponsor
- Baystate Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Springfield, Massachusetts
- Conditions
- Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
- Interventions
- Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
- Behavioral · Drug
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Detroit, Michigan